Targeting endothelial metabolism for anti-angiogenesis therapy: A pharmacological perspective

Vascular Pharmacology

Volumn 90, Issue , 2017, Pages 8-18

  Missiaen, Rindert ^a   Morales Rodriguez, Francisco ^a   Eelen, Guy ^a   Carmeliet, Peter ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CARNITINE PALMITOYLTRANSFERASE INHIBITOR; FATTY ACID; FATTY ACID BETA; HEXOSAMINE; OXFENICINE; PENTOSE PHOSPHATE; PERHEXILINE; RANOLAZINE; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; SIGNAL PEPTIDE;

AMINO ACID METABOLISM; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; CELL METABOLISM; CELL MIGRATION; CELL PROLIFERATION; CITRIC ACID CYCLE; ENDOTHELIUM CELL; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; GLYCOLYSIS; HUMAN; MALE; NUCLEOTIDE METABOLISM; OXIDATIVE PHOSPHORYLATION; PENTOSE PHOSPHATE CYCLE; PRIORITY JOURNAL; REVIEW; ANIMAL; DRUG EFFECTS; ENERGY METABOLISM; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

ANGIOGENESIS INHIBITORS; ANIMALS; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; ENERGY METABOLISM; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; SIGNAL TRANSDUCTION;

EID: 85010190253     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2017.01.001     Document Type: Review

References (178)

1. [1] Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144:5 (2011), 646–674.
2. [2] Chung, A.S., Ferrara, N., Developmental and pathological angiogenesis. Annu. Rev. Cell Dev. Biol. 27 (2011), 563–584.
3. [3] Welti, J., et al. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J. Clin. Invest. 123:8 (2013), 3190–3200.
4. [4] Ebos, J.M., Kerbel, R.S., Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat. Rev. Clin. Oncol. 8:4 (2011), 210–221.
5. [5] Verdegem, D., et al. Endothelial cell metabolism: parallels and divergences with cancer cell metabolism. Cancer Metab., 2, 2014, 19.
6. [6] Ellis, L.M., Hicklin, D.J., VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer 8:8 (2008), 579–591.
7. [7] Bergers, G., Hanahan, D., Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8:8 (2008), 592–603.
8. [8] De Bock, K., et al. Role of PFKFB3-driven glycolysis in vessel sprouting. Cell 154:3 (2013), 651–663.
9. [9] Schoors, S., et al. Fatty acid carbon is essential for dNTP synthesis in endothelial cells. Nature 520:7546 (2015), 192–197.
10. [10] De Bock, K., Georgiadou, M., Carmeliet, P., Role of endothelial cell metabolism in vessel sprouting. Cell Metab. 18:5 (2013), 634–647.
11. [11] Mazzone, M., et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 136:5 (2009), 839–851.
12. [12] Kim, Y.W., West, X.Z., Byzova, T.V., Inflammation and oxidative stress in angiogenesis and vascular disease. J. Mol. Med. (Berl.) 91:3 (2013), 323–328.
13. [13] Arroyo, A.G., Iruela-Arispe, M.L., Extracellular matrix, inflammation, and the angiogenic response. Cardiovasc. Res. 86:2 (2010), 226–235.
14. [14] Weishaupt, J.H., Hyman, T., Dikic, I., Common molecular pathways in amyotrophic lateral sclerosis and frontotemporal dementia. Trends Mol. Med. 22:9 (2016), 769–783.
15. [15] Bergers, G., Benjamin, L.E., Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 3:6 (2003), 401–410.
16. [16] Bloor, C.M., Angiogenesis during exercise and training. Angiogenesis 8:3 (2005), 263–271.
17. [17] Fraisl, P., et al. Regulation of angiogenesis by oxygen and metabolism. Dev. Cell 16:2 (2009), 167–179.
18. [18] Ryan, H.E., Lo, J., Johnson, R.S., HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J. 17:11 (1998), 3005–3015.
19. [19] Forsythe, J.A., et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 16:9 (1996), 4604–4613.
20. [20] Carmeliet, P., et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380:6573 (1996), 435–439.
21. [21] Carmeliet, P., Jain, R.K., Molecular mechanisms and clinical applications of angiogenesis. Nature 473:7347 (2011), 298–307.
22. [22] Bentley, K., et al. The role of differential VE-cadherin dynamics in cell rearrangement during angiogenesis. Nat. Cell Biol. 16:4 (2014), 309–321.
23. [23] Phng, L.K., Gerhardt, H., Angiogenesis: a team effort coordinated by notch. Dev. Cell 16:2 (2009), 196–208.
24. [24] Blanco, R., Gerhardt, H., VEGF and Notch in tip and stalk cell selection. Cold Spring Harb. Perspect. Med., 3(1), 2013, a006569.
25. [25] Quaegebeur, A., Segura, I., Carmeliet, P., Pericytes: blood-brain barrier safeguards against neurodegeneration?. Neuron 68:3 (2010), 321–323.
26. [26] Vander Heiden, M.G., Cantley, L.C., Thompson, C.B., Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:5930 (2009), 1029–1033.
27. [27] Culic, O., Gruwel, M.L., Schrader, J., Energy turnover of vascular endothelial cells. Am. J. Phys. 273:1 Pt 1 (1997), C205–C213.
28. [28] Kaczara, P., et al. Carbon monoxide shifts energetic metabolism from glycolysis to oxidative phosphorylation in endothelial cells. FEBS Lett. 590:20 (2016), 3469–3480.
29. [29] Wang, Q., et al. 2-Deoxy-D-glucose treatment of endothelial cells induces autophagy by reactive oxygen species-mediated activation of the AMP-activated protein kinase. PLoS One, 6(2), 2011, e17234.
30. [30] Li, X.B., Gu, J.D., Zhou, Q.H., Review of aerobic glycolysis and its key enzymes - new targets for lung cancer therapy. Thorac. Cancer 6:1 (2015), 17–24.
31. [31] Krutzfeldt, A., et al. Metabolism of exogenous substrates by coronary endothelial cells in culture. J. Mol. Cell. Cardiol. 22:12 (1990), 1393–1404.
32. [32] Locasale, J.W., Cantley, L.C., Metabolic flux and the regulation of mammalian cell growth. Cell Metab. 14:4 (2011), 443–451.
33. [33] Mertens, S., et al. Energetic response of coronary endothelial cells to hypoxia. Am. J. Phys. 258:3 Pt 2 (1990), H689–H694.
34. [34] Gatenby, R.A., Gillies, R.J., Why do cancers have high aerobic glycolysis?. Nat. Rev. Cancer 4:11 (2004), 891–899.
35. [35] Buchwald, P., A local glucose-and oxygen concentration-based insulin secretion model for pancreatic islets. Theor. Biol. Med. Model., 8, 2011, 20.
36. [36] Michaelis, U.R., Mechanisms of endothelial cell migration. Cell. Mol. Life Sci. 71:21 (2014), 4131–4148.
37. [37] Small, J.V., et al. The lamellipodium: where motility begins. Trends Cell Biol. 12:3 (2002), 112–120.
38. [38] Polet, F., Feron, O., Endothelial cell metabolism and tumour angiogenesis: glucose and glutamine as essential fuels and lactate as the driving force. J. Intern. Med. 273:2 (2013), 156–165.
39. [39] Aft, R.L., Zhang, F.W., Gius, D., Evaluation of 2-deoxy-D-glucose as a chemotherapeutic agent: mechanism of cell death. Br. J. Cancer 87:7 (2002), 805–812.
40. [40] Huang, C.C., et al. Glycolytic inhibitor 2-deoxyglucose simultaneously targets cancer and endothelial cells to suppress neuroblastoma growth in mice. Dis. Model. Mech. 8:10 (2015), 1247–1254.
41. [41] Merchan, J.R., et al. Antiangiogenic activity of 2-deoxy-D-glucose. PLoS One, 5(10), 2010, e13699.
42. [42] Schoors, S., et al. Partial and transient reduction of glycolysis by PFKFB3 blockade reduces pathological angiogenesis. Cell Metab. 19:1 (2014), 37–48.
43. [43] Schoors, S., et al. Incomplete and transitory decrease of glycolysis: a new paradigm for anti-angiogenic therapy?. Cell Cycle 13:1 (2014), 16–22.
44. [44] Kurtoglu, M., Maher, J.C., Lampidis, T.J., Differential toxic mechanisms of 2-deoxy-D-glucose versus 2-fluorodeoxy-D-glucose in hypoxic and normoxic tumor cells. Antioxid. Redox Signal. 9:9 (2007), 1383–1390.
45. [45] Granchi, C., Minutolo, F., Anticancer agents that counteract tumor glycolysis. ChemMedChem 7:8 (2012), 1318–1350.
46. [46] Ganapathy-Kanniappan, S., Geschwind, J.F., Tumor glycolysis as a target for cancer therapy: progress and prospects. Mol. Cancer, 12, 2013, 152.
47. [47] Tennant, D.A., Duran, R.V., Gottlieb, E., Targeting metabolic transformation for cancer therapy. Nat. Rev. Cancer 10:4 (2010), 267–277.
48. [48] Hue, L., Rider, M.H., Role of fructose 2,6-bisphosphate in the control of glycolysis in mammalian tissues. Biochem. J. 245:2 (1987), 313–324.
49. [49] Yalcin, A., et al. Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer. Exp. Mol. Pathol. 86:3 (2009), 174–179.
50. [50] Bolanos, J.P., Adapting glycolysis to cancer cell proliferation: the MAPK pathway focuses on PFKFB3. Biochem. J. 452:3 (2013), e7–e9.
51. [51] Bando, H., et al. Phosphorylation of the 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase/PFKFB3 family of glycolytic regulators in human cancer. Clin. Cancer Res. 11:16 (2005), 5784–5792.
52. [52] Smith, G.A., et al. Vascular endothelial growth factors: multitasking functionality in metabolism, health and disease. J. Inherit. Metab. Dis. 38:4 (2015), 753–763.
53. [53] Yeh, W.L., Lin, C.J., Fu, W.M., Enhancement of glucose transporter expression of brain endothelial cells by vascular endothelial growth factor derived from glioma exposed to hypoxia. Mol. Pharmacol. 73:1 (2008), 170–177.
54. [54] Novellasdemunt, L., et al. PFKFB3 activation in cancer cells by the p38/MK2 pathway in response to stress stimuli. Biochem. J. 452:3 (2013), 531–543.
55. [55] Xu, Y., et al. Endothelial PFKFB3 plays a critical role in angiogenesis. Arterioscler. Thromb. Vasc. Biol. 34:6 (2014), 1231–1239.
56. [56] Cantelmo, A.R., et al. Inhibition of the glycolytic activator PFKFB3 in endothelial cells induces tumor vessel normalization, impairs metastasis and improves chemotherapy. Cancer Cell 30:6 (2016), 968–985.
57. [57] Seo, M., et al. Structure-based development of small molecule PFKFB3 inhibitors: a framework for potential cancer therapeutic agents targeting the Warburg effect. PLoS One, 6(9), 2011, e24179.
58. [58] Clem, B., et al. Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth. Mol. Cancer Ther. 7:1 (2008), 110–120.
59. [59] Clem, B.F., et al. Targeting 6-phosphofructo-2-kinase ( PFKFB3) as a therapeutic strategy against cancer. Mol. Cancer Ther. 12:8 (2013), 1461–1470.
60. [60] Telang, Sucheta, O'Neal, Julie, Tapolsky, Gilles, Clem, Brian, Kerr, Alan, Imbert-Ferndandez, Yoannis, Chesney, Jason, Discovery of a PFKFB3 inhibitor for phase I trial testing that synergizes with the B-Raf inhibitor vemurafenib. Cancer Metab., 2(Suppl. 1), 2014, 14.
61. [61] Rouaud, F., et al. Regulation of NADPH-dependent Nitric Oxide and reactive oxygen species signalling in endothelial and melanoma cells by a photoactive NADPH analogue. Oncotarget 5:21 (2014), 10650–10664.
62. [62] Fan, J., et al. Quantitative flux analysis reveals folate-dependent NADPH production. Nature 510:7504 (2014), 298–302.
63. [63] Leopold, J.A., et al. Glucose-6-phosphate dehydrogenase overexpression decreases endothelial cell oxidant stress and increases bioavailable nitric oxide. Arterioscler. Thromb. Vasc. Biol. 23:3 (2003), 411–417.
64. [64] Anastasiou, D., et al. Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science 334:6060 (2011), 1278–1283.
65. [65] Lunt, S.Y., Vander Heiden, M.G., Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu. Rev. Cell Dev. Biol. 27 (2011), 441–464.
66. [66] Dobrina, A., Rossi, F., Metabolic properties of freshly isolated bovine endothelial cells. Biochim. Biophys. Acta 762:2 (1983), 295–301.
67. [67] Stapor, P., et al. Angiogenesis revisited - role and therapeutic potential of targeting endothelial metabolism. J. Cell Sci. 127:Pt 20 (2014), 4331–4341.
68. [68] Kuehne, A., et al. Acute activation of oxidative pentose phosphate pathway as first-line response to oxidative stress in human skin cells. Mol. Cell 59:3 (2015), 359–371.
69. [69] Tyson, R.L., Perron, J., Sutherland, G.R., 6-Aminonicotinamide inhibition of the pentose phosphate pathway in rat neocortex. Neuroreport 11:9 (2000), 1845–1848.
70. [70] Hothersall, J.S., Gordge, M., Noronha-Dutra, A.A., Inhibition of NADPH supply by 6-aminonicotinamide: effect on glutathione, nitric oxide and superoxide in J774 cells. FEBS Lett. 434:1–2 (1998), 97–100.
71. [71] Perlia, C.P., et al. Clinical use of 6-aminonicotinamide in patients with disseminated neoplastic disease. Cancer 14 (1961), 644–648.
72. [72] Vizan, P., et al. Characterization of the metabolic changes underlying growth factor angiogenic activation: identification of new potential therapeutic targets. Carcinogenesis 30:6 (2009), 946–952.
73. [73] Taparra, K., Tran, P.T., Zachara, N.E., Hijacking the hexosamine biosynthetic pathway to promote EMT-mediated neoplastic phenotypes. Front. Oncol., 6, 2016, 85.
74. [74] Marshall, S., Bacote, V., Traxinger, R.R., Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. J. Biol. Chem. 266:8 (1991), 4706–4712.
75. [75] Laczy, B., et al. Protein O-GlcNAcylation: a new signaling paradigm for the cardiovascular system. Am. J. Physiol. Heart Circ. Physiol. 296:1 (2009), H13–H28.
76. [76] Qian, Y., et al. Discovery of 1-arylcarbonyl-6,7-dimethoxyisoquinoline derivatives as glutamine fructose-6-phosphate amidotransferase (GFAT) inhibitors. Bioorg. Med. Chem. Lett. 21:21 (2011), 6264–6269.
77. [77] McKnight, G.L., et al. Molecular cloning, cDNA sequence, and bacterial expression of human glutamine:fructose-6-phosphate amidotransferase. J. Biol. Chem. 267:35 (1992), 25208–25212.
78. [78] Zachara, N.E., Hart, G.W., O-GlcNAc a sensor of cellular state: the role of nucleocytoplasmic glycosylation in modulating cellular function in response to nutrition and stress. Biochim. Biophys. Acta 1673:1–2 (2004), 13–28.
79. [79] Nacev, B.A., et al. The antifungal drug itraconazole inhibits vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, trafficking, and signaling in endothelial cells. J. Biol. Chem. 286:51 (2011), 44045–44056.
80. [80] Bruns, A.F., et al. Ligand-stimulated VEGFR2 signaling is regulated by co-ordinated trafficking and proteolysis. Traffic 11:1 (2010), 161–174.
81. [81] Luo, B., Soesanto, Y., McClain, D.A., Protein modification by O-linked GlcNAc reduces angiogenesis by inhibiting Akt activity in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 28:4 (2008), 651–657.
82. [82] Takeuchi, H., et al. Site-specific O-glucosylation of the epidermal growth factor-like (EGF) repeats of notch: efficiency of glycosylation is affected by proper folding and amino acid sequence of individual EGF repeats. J. Biol. Chem. 287:41 (2012), 33934–33944.
83. [83] Benedito, R., et al. The notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis. Cell 137:6 (2009), 1124–1135.
84. [84] Yang, L.T., et al. Fringe glycosyltransferases differentially modulate Notch1 proteolysis induced by Delta1 and Jagged1. Mol. Biol. Cell 16:2 (2005), 927–942.
85. [85] Rajapakse, A.G., et al. The hexosamine biosynthesis inhibitor azaserine prevents endothelial inflammation and dysfunction under hyperglycemic condition through antioxidant effects. Am. J. Physiol. Heart Circ. Physiol. 296:3 (2009), H815–H822.
86. [87] Federici, M., et al. Insulin-dependent activation of endothelial nitric oxide synthase is impaired by O-linked glycosylation modification of signaling proteins in human coronary endothelial cells. Circulation 106:4 (2002), 466–472.
87. [86] Gross, M.I., et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol. Cancer Ther. 13:4 (2014), 890–901.
88. [88] Blake, R., Trounce, I.A., Mitochondrial dysfunction and complications associated with diabetes. Biochim. Biophys. Acta 1840:4 (2014), 1404–1412.
89. [89] Nielsen, T.S., et al. Dissecting adipose tissue lipolysis: molecular regulation and implications for metabolic disease. J. Mol. Endocrinol. 52:3 (2014), R199–R222.
90. [90] Frayn, K.N., et al. Integrative physiology of human adipose tissue. Int. J. Obes. Relat. Metab. Disord. 27:8 (2003), 875–888.
91. [91] Lopaschuk, G.D., Jaswal, J.S., Energy metabolic phenotype of the cardiomyocyte during development, differentiation, and postnatal maturation. J. Cardiovasc. Pharmacol. 56:2 (2010), 130–140.
92. [92] Kelley, D.E., Skeletal muscle fat oxidation: timing and flexibility are everything. J. Clin. Invest. 115:7 (2005), 1699–1702.
93. [93] Vo, T.D., Greenberg, H.J., Palsson, B.O., Reconstruction and functional characterization of the human mitochondrial metabolic network based on proteomic and biochemical data. J. Biol. Chem. 279:38 (2004), 39532–39540.
94. [94] Wang, W., et al. Increased AMP:ATP ratio and AMP-activated protein kinase activity during cellular senescence linked to reduced HuR function. J. Biol. Chem. 278:29 (2003), 27016–27023.
95. [95] Reihill, J.A., Ewart, M.A., Salt, I.P., The role of AMP-activated protein kinase in the functional effects of vascular endothelial growth factor-A and -B in human aortic endothelial cells. Vasc. Cell, 3, 2011, 9.
96. [96] Corton, J.M., et al. 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells?. Eur. J. Biochem. 229:2 (1995), 558–565.
97. [97] Foster, D.W., Malonyl-CoA: the regulator of fatty acid synthesis and oxidation. J. Clin. Invest. 122:6 (2012), 1958–1959.
98. [98] Smolkova, K., Jezek, P., The role of mitochondrial NADPH-dependent isocitrate dehydrogenase in cancer cells. Int. J. Cell Biol., 2012, 2012, 273947.
99. [99] Jeppesen, J., Kiens, B., Regulation and limitations to fatty acid oxidation during exercise. J. Physiol. 590:5 (2012), 1059–1068.
100. [100] Stahl, A., et al. Insulin causes fatty acid transport protein translocation and enhanced fatty acid uptake in adipocytes. Dev. Cell 2:4 (2002), 477–488.
101. [101] Ehehalt, R., et al. Uptake of long chain fatty acids is regulated by dynamic interaction of FAT/CD36 with cholesterol/sphingolipid enriched microdomains (lipid rafts). BMC Cell Biol., 9, 2008, 45.
102. [102] Schwenk, R.W., et al. Fatty acid transport across the cell membrane: regulation by fatty acid transporters. Prostaglandins Leukot. Essent. Fat. Acids 82:4–6 (2010), 149–154.
103. [103] Kamp, F., et al. Rapid flip-flop of oleic acid across the plasma membrane of adipocytes. J. Biol. Chem. 278:10 (2003), 7988–7995.
104. [104] Huang, H., et al. Liver fatty acid-binding protein targets fatty acids to the nucleus. Real time confocal and multiphoton fluorescence imaging in living cells. J. Biol. Chem. 277:32 (2002), 29139–29151.
105. [105] Coburn, C.T., et al. Defective uptake and utilization of long chain fatty acids in muscle and adipose tissues of CD36 knockout mice. J. Biol. Chem. 275:42 (2000), 32523–32529.
106. [106] Watanabe, K., et al. Myocardial CD36 expression and fatty acid accumulation in patients with type I and II CD36 deficiency. Ann. Nucl. Med. 12:5 (1998), 261–266.
107. [107] Mitchell, R.W., et al. Fatty acid transport protein expression in human brain and potential role in fatty acid transport across human brain microvessel endothelial cells. J. Neurochem. 117:4 (2011), 735–746.
108. [108] Endemann, G., et al. CD36 is a receptor for oxidized low density lipoprotein. J. Biol. Chem. 268:16 (1993), 11811–11816.
109. [109] Schafer, Z.T., et al. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 461:7260 (2009), 109–113.
110. [110] Dagher, Z., et al. Acute regulation of fatty acid oxidation and amp-activated protein kinase in human umbilical vein endothelial cells. Circ. Res. 88:12 (2001), 1276–1282.
111. [111] Hulsmann, W.C., Dubelaar, M.L., Aspects of fatty acid metabolism in vascular endothelial cells. Biochimie 70:5 (1988), 681–686.
112. [112] Yang, C., et al. Glutamine oxidation maintains the TCA cycle and cell survival during impaired mitochondrial pyruvate transport. Mol Cell. 56:3 (2012), 414–424.
113. [113] Cheng, T., et al. Pyruvate carboxylase is required for glutamine-independent growth of tumor cells. Proc. Natl. Acad. Sci. U. S. A. 108:21 (2011), 8674–8679.
114. [114] Pike, L.S., et al. Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells. Biochim. Biophys. Acta 1807:6 (2011), 726–734.
115. [115] Tirado-Velez, J.M., et al. Inhibition of fatty acid metabolism reduces human myeloma cells proliferation. PLoS One, 7(9), 2012, e46484.
116. [116] Schlaepfer, I.R., et al. Lipid catabolism via CPT1 as a therapeutic target for prostate cancer. Mol. Cancer Ther. 13:10 (2014), 2361–2371.
117. [117] Patella, F., et al. Proteomics-based metabolic modeling reveals that fatty acid oxidation (FAO) controls endothelial cell (EC) permeability. Mol. Cell. Proteomics 14:3 (2015), 621–634.
118. [118] Newell, M.K., Newell, E., Villobos-Menvey, E., Compositions of UCP inhibitors, Fas antibody, a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor. Google Patents (Patent number: US7510710 B2), 2009.
119. [119] Holubarsch, C.J., et al. A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study. Clin. Sci. (Lond.) 113:4 (2007), 205–212.
120. [120] Maarman, G., et al. Effect of chronic CPT-1 inhibition on myocardial ischemia-reperfusion injury (I/R) in a model of diet-induced obesity. Cardiovasc. Drugs Ther. 26:3 (2012), 205–216.
121. [121] Korb, H., et al. Changes in myocardial substrate utilisation and protection of ischemic stressed myocardium by oxfenicine [(S)-4-hydroxyphenylglycine]. Naunyn Schmiedeberg's Arch. Pharmacol. 327:1 (1984), 70–74.
122. [122] Kennedy, J.A., et al. Effect of perhexiline and oxfenicine on myocardial function and metabolism during low-flow ischemia/reperfusion in the isolated rat heart. J. Cardiovasc. Pharmacol. 36:6 (2000), 794–801.
123. [123] Kennedy, J.A., Unger, S.A., Horowitz, J.D., Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Biochem. Pharmacol. 52:2 (1996), 273–280.
124. [124] Hamdan, M., et al. Inhibition of mitochondrial carnitine palmitoyltransferase-1 by a trimetazidine derivative, S-15176. Pharmacol. Res. 44:2 (2001), 99–104.
125. [125] Singh, S., et al. Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome. Futur. Cardiol. 10:6 (2014), 693–698.
126. [126] Beadle, R.M., et al. Improvement in cardiac energetics by perhexiline in heart failure due to dilated cardiomyopathy. JACC Heart Fail. 3:3 (2015), 202–211.
127. [127] Kennedy, J.A., et al. Effect of the anti-anginal agent, perhexiline, on neutrophil, valvular and vascular superoxide formation. Eur. J. Pharmacol. 531:1–3 (2006), 13–19.
128. [128] Page, R.L. 2nd, et al. Comparative effectiveness of ranolazine versus traditional therapies in chronic stable angina pectoris and concomitant diabetes mellitus and impact on health care resource utilization and cardiac interventions. Am. J. Cardiol. 116:9 (2015), 1321–1328.
129. [129] Babalis, D., et al. Effects of ranolazine on left ventricular diastolic and systolic function in patients with chronic coronary disease and stable angina. Hell. J. Cardiol. 56:3 (2015), 237–241.
130. [130] Bergman, G., et al. Beneficial effect of enhanced myocardial carbohydrate utilisation after oxfenicine (L-hydroxyphenylglycine) in angina pectoris. Eur. Heart J. 1:4 (1980), 247–253.
131. [131] Rosa, G.M., et al. Ranolazine for the treatment of atrial fibrillation. Expert Opin. Investig. Drugs 24:6 (2015), 825–836.
132. [132] De Ferrari, G.M., et al. Ranolazine in the treatment of atrial fibrillation: results of the dose-ranging RAFFAELLO (Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion) study. Heart Rhythm. 12:5 (2015), 872–878.
133. [133] Hillgartner, F., Salati, L.M., Goodridge, A.G., Physiological and molecular mechanisms involved in nutritional regulation of fatty-acid synthesis. Physiol. Rev. 75:1 (1995), 47–76.
134. [134] Flavin, R., et al. Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol. 6:4 (2010), 551–562.
135. [135] Zaidi, N., et al. Lipogenesis and lipolysis: the pathways exploited by the cancer cells to acquire fatty acids. Prog. Lipid Res. 52:4 (2013), 585–589.
136. [136] Currie, E., et al. Cellular fatty acid metabolism and cancer. Cell Metab. 18:2 (2013), 153–161.
137. [137] Ogino, S., et al. Cohort study of fatty acid synthase expression and patient survival in colon cancer. J. Clin. Oncol. 26:35 (2008), 5713–5720.
138. [138] Shurbaji, M.S., Kalbfleisch, J.H., Thurmond, T.S., Immunohistochemical detection of a fatty acid synthase (OA-519) as a predictor of progression of prostate cancer. Hum. Pathol. 27:9 (1996), 917–921.
139. [139] Visca, P., et al. Fatty acid synthase (FAS) is a marker of increased risk of recurrence in lung carcinoma. Anticancer Res. 24:6 (2004), 4169–4173.
140. [140] Yang, C.S., et al. Fatty acid synthase inhibition engages a novel caspase-2 regulatory mechanism to induce ovarian cancer cell death. Oncogene 34:25 (2015), 3264–3272.
141. [141] Peck, B., Schulze, A., Lipid desaturation - the next step in targeting lipogenesis in cancer?. FEBS J. 283:15 (2016), 2767–2778.
142. [142] Wei, X., et al. De novo lipogenesis maintains vascular homeostasis through endothelial nitric-oxide synthase (eNOS) palmitoylation. J. Biol. Chem. 286:4 (2011), 2933–2945.
143. [143] Browne, C.D., Hindmarsh, E.J., Smith, J.W., Inhibition of endothelial cell proliferation and angiogenesis by orlistat, a fatty acid synthase inhibitor. FASEB J. 20:12 (2006), 2027–2035.
144. [144] Seguin, F., et al. The fatty acid synthase inhibitor orlistat reduces experimental metastases and angiogenesis in B16-F10 melanomas. Br. J. Cancer 107:6 (2012), 977–987.
145. [145] Zaytseva, Y.Y., et al. Cancer cell-associated fatty acid synthase activates endothelial cells and promotes angiogenesis in colorectal cancer. Carcinogenesis 35:6 (2014), 1341–1351.
146. [146] Zhao, Y., Vanhoutte, P.M., Leung, S.W., Vascular nitric oxide: beyond eNOS. J. Pharmacol. Sci. 129:2 (2015), 83–94.
147. [147] Tuteja, N., et al. Nitric oxide as a unique bioactive signaling messenger in physiology and pathophysiology. J. Biomed. Biotechnol. 2004:4 (2004), 227–237.
148. [148] Guo, J.P., et al. Mechanisms of vascular preservation by a novel NO donor following rat carotid artery intimal injury. Am. J. Phys. 269:3 Pt 2 (1995), H1122–H1131.
149. [149] DeBerardinis, R.J., Cheng, T., Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 29:3 (2010), 313–324.
150. [150] Lohmann, R., Souba, W.W., Bode, B.P., Rat liver endothelial cell glutamine transporter and glutaminase expression contrast with parenchymal cells. Am. J. Phys. 276:3 Pt 1 (1999), G743–G750.
151. [151] Unterluggauer, H., et al. Premature senescence of human endothelial cells induced by inhibition of glutaminase. Biogerontology 9:4 (2008), 247–259.
152. [152] Wu, G., et al. Presence of glutamine:fructose-6-phosphate amidotransferase for glucosamine-6-phosphate synthesis in endothelial cells: effects of hyperglycaemia and glutamine. Diabetologia 44:2 (2001), 196–202.
153. [153] Gao, P., et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458:7239 (2009), 762–765.
154. [154] Hu, W., et al. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc. Natl. Acad. Sci. U. S. A. 107:16 (2010), 7455–7460.
155. [155] Wise, D.R., et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc. Natl. Acad. Sci. U. S. A. 105:48 (2008), 18782–18787.
156. [156] de la Rosa, V., et al. A novel glutaminase isoform in mammalian tissues. Neurochem. Int. 55:1–3 (2009), 76–84.
157. [157] Maggs, D.G., et al. Interstitial fluid concentrations of glycerol, glucose, and amino acids in human quadricep muscle and adipose tissue. Evidence for significant lipolysis in skeletal muscle. J. Clin. Invest. 96:1 (1995), 370–377.
158. [158] Souba, W.W., Glutamine and cancer. Ann. Surg. 218:6 (1993), 715–728.
159. [159] Abcouwer, S.F., et al. Molecular regulation of lung endothelial glutamine synthetase expression. Surgery 118:2 (1995), 325–334 (discussion 335).
160. [160] Kobayashi, T., et al. Changes in aortic endothelial gene expressions and relaxation responses following chronic short-term insulin treatment in diabetic rats. Atherosclerosis 185:1 (2006), 47–57.
161. [161] Qi, L., et al. Association between a genetic variant related to glutamic acid metabolism and coronary heart disease in individuals with type 2 diabetes. JAMA 310:8 (2013), 821–828.
162. [162] Newsholme, P., et al. Glutamine and glutamate—their central role in cell metabolism and function. Cell Biochem. Funct. 21:1 (2003), 1–9.
163. [163] Amelio, I., et al. Serine and glycine metabolism in cancer. Trends Biochem. Sci. 39:4 (2014), 191–198.
164. [164] Ma, X., et al. Genomic approach to identify factors that drive the formation of three-dimensional structures by EA.hy926 endothelial cells. PLoS One, 8(5), 2013, e64402.
165. [165] Mishra, R.C., et al. Nitric oxide synthase inhibition promotes endothelium-dependent vasodilatation and the antihypertensive effect of L-serine. Hypertension 51:3 (2008), 791–796.
166. [166] Mishra, R.C., et al. L-Serine lowers while glycine increases blood pressure in chronic L-NAME-treated and spontaneously hypertensive rats. J. Hypertens. 26:12 (2008), 2339–2348.
167. [167] Jang, C., et al. A branched-chain amino acid metabolite drives vascular fatty acid transport and causes insulin resistance. Nat. Med. 22:4 (2016), 421–426.
168. [168] Yang, Y., et al. L-Leucine and NO-mediated cardiovascular function. Amino Acids 47:3 (2015), 435–447.
169. [169] Wu, G., et al. Glutamine metabolism to glucosamine is necessary for glutamine inhibition of endothelial nitric oxide synthesis. Biochem. J. 353:Pt 2 (2001), 245–252.
170. [170] Durante, W., et al. Glutaminase stimulates the proliferation of human endothelial cells. FASEB J., 30, 2016 (no. 1 Supplement 957.3).
171. [171] Ray, P.D., Huang, B.W., Tsuji, Y., Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell. Signal. 24:5 (2012), 981–990.
172. [172] Boveris, A., Cadenas, E., Mitochondrial production of superoxide anions and its relationship to the antimycin insensitive respiration. FEBS Lett. 54:3 (1975), 311–314.
173. [173] Liu, Y., Fiskum, G., Schubert, D., Generation of reactive oxygen species by the mitochondrial electron transport chain. J. Neurochem. 80:5 (2002), 780–787.
174. [174] Zhang, D.X., Gutterman, D.D., Mitochondrial reactive oxygen species-mediated signaling in endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 292:5 (2007), H2023–H2031.
175. [175] Kaneto, H., et al. Role of reactive oxygen species in the progression of type 2 diabetes and atherosclerosis. Mediat. Inflamm., 2010, 2010, 453892.
176. [176] Ouedraogo, R., et al. Adiponectin suppression of high-glucose-induced reactive oxygen species in vascular endothelial cells: evidence for involvement of a cAMP signaling pathway. Diabetes 55:6 (2006), 1840–1846.
177. [177] Makino, A., Scott, B.T., Dillmann, W.H., Mitochondrial fragmentation and superoxide anion production in coronary endothelial cells from a mouse model of type 1 diabetes. Diabetologia 53:8 (2010), 1783–1794.
178. [178] Dranka, B.P., Hill, B.G., Darley-Usmar, V.M., Mitochondrial reserve capacity in endothelial cells: the impact of nitric oxide and reactive oxygen species. Free Radic. Biol. Med. 48:7 (2010), 905–914.